EA200400888A1 - Фармацевтически приемлемые тельца, несущие фосфат глицерина - Google Patents
Фармацевтически приемлемые тельца, несущие фосфат глицеринаInfo
- Publication number
- EA200400888A1 EA200400888A1 EA200400888A EA200400888A EA200400888A1 EA 200400888 A1 EA200400888 A1 EA 200400888A1 EA 200400888 A EA200400888 A EA 200400888A EA 200400888 A EA200400888 A EA 200400888A EA 200400888 A1 EA200400888 A1 EA 200400888A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- synthetic
- pharmaceuticalally
- acceptable
- relates
- inflammatory
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G19/00—Compounds of tin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G15/00—Compounds of gallium, indium or thallium
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/24—Electrically-conducting paints
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
Abstract
Настоящее изобретение относится к трёхмерным синтетическим и полусинтетическим композициям, обладающим биологической активностью, и к их применениям для лечения и/или профилактики различных нарушений у пациентов-млекопитающих. Более конкретно оно относится к приготовлению и применению синтетических и полусинтетических телец, таких как липосомы, которые после введения в организм пациента дают полезные противовоспалительные, органозащищающие и иммунорегуляторные эффекты. Изобретение относится также к лечению и композициям для облегчения воспалительных и аутоиммунных заболеваний и их симптомов.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002368656A CA2368656A1 (en) | 2002-01-21 | 2002-01-21 | Receptor-ligand pairing for anti-inflammatory response |
US5138102A | 2002-01-22 | 2002-01-22 | |
US35142702P | 2002-01-28 | 2002-01-28 | |
US36462002P | 2002-03-18 | 2002-03-18 | |
US37210602P | 2002-04-15 | 2002-04-15 | |
US40085702P | 2002-08-02 | 2002-08-02 | |
PCT/CA2003/000065 WO2003061667A1 (en) | 2002-01-21 | 2003-01-21 | Pharmaceutically acceptable phosphate-glycerol carrying bodies |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200400888A1 true EA200400888A1 (ru) | 2005-04-28 |
EA007426B1 EA007426B1 (ru) | 2006-10-27 |
Family
ID=27617925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200400888A EA007426B1 (ru) | 2002-01-21 | 2003-01-21 | Фармацевтически приемлемые тельца, несущие фосфат глицерина |
Country Status (14)
Country | Link |
---|---|
US (3) | US20030175334A1 (ru) |
EP (2) | EP1467740A1 (ru) |
JP (2) | JP2005515243A (ru) |
KR (1) | KR20040089118A (ru) |
CN (1) | CN1620301A (ru) |
AR (2) | AR047005A1 (ru) |
BR (2) | BR0307018A (ru) |
CA (5) | CA2368656A1 (ru) |
EA (1) | EA007426B1 (ru) |
MA (1) | MA27168A1 (ru) |
MX (1) | MXPA04007042A (ru) |
PE (1) | PE20030973A1 (ru) |
TW (2) | TW200302281A (ru) |
WO (3) | WO2003061666A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050058698A1 (en) * | 2002-01-21 | 2005-03-17 | Nolan Yvonne Mairead | Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease |
WO2004082688A1 (en) * | 2003-03-20 | 2004-09-30 | Vasogen Ireland Limited | Phosphatidylglycerol (pg) receptor agonists and antagonists |
CA2533084A1 (en) * | 2003-07-21 | 2005-01-27 | Vasogen Ireland Limited | Liposomes containing phosphate glycerol groups for treating acute inflammatory condition |
US20060008517A1 (en) * | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
EA200700626A1 (ru) * | 2004-09-15 | 2007-10-26 | Васоджен Айеленд Лимитед | Лечение множественного склероза |
WO2006107107A1 (ja) * | 2005-04-01 | 2006-10-12 | Fumitaka Ohsuzu | リン脂質小胞体を含む心筋保護剤および虚血・再潅流時の心筋障害を予防する方法 |
US20070071805A1 (en) * | 2005-09-26 | 2007-03-29 | Vasogen Ireland Ltd. | Treatment of inflammation and vascular abnormalities of the eye |
EP1933813A4 (en) * | 2005-10-11 | 2013-02-27 | Univ Pittsburgh | SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER |
WO2007131329A1 (en) * | 2006-05-12 | 2007-11-22 | Vasogen Ireland Limited | Treatment of ubiquitin-proteasome system dysfunction related disorders |
NZ598906A (en) | 2009-08-21 | 2014-08-29 | Targeted Delivery Technologies Ltd | Vesicular formulations |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
RS60951B1 (sr) * | 2012-06-14 | 2020-11-30 | Univ Bern | Lipozomi prilagođeni za lečenje bakterijskih infekcija |
JP6417648B2 (ja) * | 2013-07-30 | 2018-11-07 | 株式会社豊田中央研究所 | エタノールアミンリン酸の利用 |
AU2015242791B2 (en) * | 2014-04-04 | 2017-08-17 | Osaka University | Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors |
WO2016185816A1 (ja) * | 2015-05-18 | 2016-11-24 | 不二製油グループ本社株式会社 | IL-1β産生抑制作用を有する食品添加用組成物 |
LT3316857T (lt) | 2015-06-30 | 2021-11-25 | Sequessome Technology Holdings Limited | Daugiafazės kompozicijos |
CN116549393A (zh) * | 2017-03-02 | 2023-08-08 | 康柏辛股份有限公司 | 抑制生物膜形成的脂质体 |
CN115531399A (zh) * | 2022-09-15 | 2022-12-30 | 首都医科大学 | 溶血磷脂酰胆碱在治疗阿尔茨海默病中的应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2518718A1 (fr) * | 1981-12-23 | 1983-06-24 | Djelalian Madeleine | Procede pour capter et exploiter au maximum le rayonnement solaire global, dispositifs pour la mise en oeuvre de ce procede et capteurs solaires en resultant |
US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4789633A (en) * | 1984-04-19 | 1988-12-06 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
US4812314A (en) * | 1986-02-24 | 1989-03-14 | Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization | Lipid replacement therapy |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5229376A (en) * | 1986-09-25 | 1993-07-20 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated plant-derived phosphatidylinositol (PI) compositions for the prevention of mitogenically induced cell proliferation |
US4963297A (en) * | 1987-12-22 | 1990-10-16 | The Liposome Company, Inc. | Spontaneous vesticulation of multilamellar liposomes |
US4863739A (en) * | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
FR2617170B1 (fr) * | 1987-06-25 | 1989-12-22 | Inst Nat Sante Rech Med | Nouveaux derives peptidiques et leur application notamment en therapeutique |
AU633078B2 (en) * | 1989-04-04 | 1993-01-21 | Alcon Laboratories, Inc. | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions |
EP0469082B1 (en) * | 1989-04-18 | 1995-04-05 | Vestar, Inc. | Liposomal targeting of ischemic tissue |
FR2658418B1 (fr) * | 1990-02-20 | 1994-09-02 | Synthelabo | Compositions pharmaceutiques a base de phospholipides. |
US5188951A (en) * | 1990-04-17 | 1993-02-23 | The Liposome Company, Inc. | Enzymatic synthesis of soluble phosphatides from phospholipids |
DE4018767A1 (de) * | 1990-06-12 | 1991-12-19 | Braun Melsungen Ag | Wirkstofffreie liposomen zur behandlung von atherosklerose |
US5556637A (en) * | 1990-08-06 | 1996-09-17 | A. Nattermann & Cie. Gmbh | Water containing liposome system |
IT1249063B (it) * | 1991-05-28 | 1995-02-11 | Fidia Spa | Impiego di derivati fosfolipidici per la preparazione di composizioni farmaceutiche aventi attivita' immunosoppressiva |
WO1994013692A1 (en) * | 1992-12-10 | 1994-06-23 | Regents Of The University Of Minnesota | Polypeptides useful for treating inflammatory disorders |
US5637315A (en) * | 1993-01-04 | 1997-06-10 | Thomas Jefferson University | Treatment of disease states induced by oxidative stress |
ES2072223B1 (es) * | 1993-11-25 | 1996-03-16 | Lipotec Sa | Liposomas encapsulando doxorubicina. |
US5746223A (en) * | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
AU1751795A (en) * | 1994-03-04 | 1995-09-18 | University Of British Columbia, The | Liposome compositions and methods for the treatment of atherosclerosis |
US6139871A (en) * | 1995-07-26 | 2000-10-31 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
JPH08183740A (ja) * | 1994-12-28 | 1996-07-16 | Nippon Steel Corp | 細胞接着阻害剤及び該阻害剤を含む抗炎症剤 |
US5643599A (en) * | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
US5741514A (en) * | 1995-08-31 | 1998-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for reducing serum lipoprotein(a) concentration |
EP0850064A1 (en) * | 1995-09-14 | 1998-07-01 | Lxr Biotechnology Inc. | Compositions with anti-apoptotic activity, containing a mixture of phospholipids |
US5736157A (en) * | 1995-10-11 | 1998-04-07 | Williams; Kevin Jon | Method of regulating cholesterol related genes, enzymes and other compounds, and pharmaceutical compositions |
US6491922B1 (en) * | 1996-02-09 | 2002-12-10 | Cornell Research Foundation, Inc. | Methods and compounds for treating autoimmune and vascular disease |
CA2250219C (en) * | 1996-03-28 | 2008-10-07 | Hayat Onyuksel | Materials and methods for making improved liposome compositions |
US20020115609A1 (en) * | 1997-07-14 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
JPH11308562A (ja) * | 1998-04-20 | 1999-11-05 | Minolta Co Ltd | デジタルカメラシステム |
US6251932B1 (en) * | 1998-09-25 | 2001-06-26 | Asta Medica Ag | Immunophilin ligands |
AU7833601A (en) * | 2000-07-31 | 2002-02-13 | Daniel L Sparks | Charged lipid compositions and methods for their use |
-
2002
- 2002-01-21 CA CA002368656A patent/CA2368656A1/en not_active Abandoned
-
2003
- 2003-01-17 CA CA002416791A patent/CA2416791A1/en not_active Abandoned
- 2003-01-21 JP JP2003561611A patent/JP2005515243A/ja active Pending
- 2003-01-21 EP EP03700265A patent/EP1467740A1/en not_active Withdrawn
- 2003-01-21 CA CA002473490A patent/CA2473490A1/en not_active Abandoned
- 2003-01-21 BR BR0307018-2A patent/BR0307018A/pt not_active IP Right Cessation
- 2003-01-21 AR ARP030100172A patent/AR047005A1/es not_active Application Discontinuation
- 2003-01-21 TW TW092101236A patent/TW200302281A/zh unknown
- 2003-01-21 WO PCT/CA2003/000064 patent/WO2003061666A1/en active Application Filing
- 2003-01-21 EP EP20030700266 patent/EP1467741A1/en not_active Withdrawn
- 2003-01-21 BR BR0307041-7A patent/BR0307041A/pt not_active IP Right Cessation
- 2003-01-21 PE PE2003000064A patent/PE20030973A1/es not_active Application Discontinuation
- 2003-01-21 CA CA002473395A patent/CA2473395A1/en not_active Abandoned
- 2003-01-21 TW TW092101231A patent/TWI283181B/zh not_active IP Right Cessation
- 2003-01-21 CA CA002471740A patent/CA2471740A1/en not_active Abandoned
- 2003-01-21 WO PCT/CA2003/000065 patent/WO2003061667A1/en active Application Filing
- 2003-01-21 US US10/348,600 patent/US20030175334A1/en not_active Abandoned
- 2003-01-21 AR ARP030100173A patent/AR038203A1/es not_active Application Discontinuation
- 2003-01-21 MX MXPA04007042A patent/MXPA04007042A/es not_active Application Discontinuation
- 2003-01-21 WO PCT/CA2003/000066 patent/WO2003061620A2/en not_active Application Discontinuation
- 2003-01-21 CN CNA03802537XA patent/CN1620301A/zh active Pending
- 2003-01-21 US US10/348,601 patent/US20040013718A1/en not_active Abandoned
- 2003-01-21 KR KR10-2004-7011280A patent/KR20040089118A/ko not_active Application Discontinuation
- 2003-01-21 EA EA200400888A patent/EA007426B1/ru not_active IP Right Cessation
- 2003-01-21 JP JP2003561610A patent/JP2005515242A/ja active Pending
-
2004
- 2004-07-16 MA MA27788A patent/MA27168A1/fr unknown
-
2007
- 2007-11-28 US US11/946,785 patent/US20080160074A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MA27168A1 (fr) | 2005-01-03 |
CA2471740A1 (en) | 2003-07-31 |
WO2003061666A1 (en) | 2003-07-31 |
JP2005515242A (ja) | 2005-05-26 |
AR038203A1 (es) | 2005-01-05 |
CA2416791A1 (en) | 2003-07-21 |
KR20040089118A (ko) | 2004-10-20 |
CA2473490A1 (en) | 2003-07-31 |
BR0307018A (pt) | 2005-02-09 |
CN1620301A (zh) | 2005-05-25 |
EA007426B1 (ru) | 2006-10-27 |
CA2473395A1 (en) | 2003-07-31 |
EP1467741A1 (en) | 2004-10-20 |
WO2003061667A1 (en) | 2003-07-31 |
CA2368656A1 (en) | 2003-07-21 |
WO2003061620A2 (en) | 2003-07-31 |
MXPA04007042A (es) | 2005-06-20 |
BR0307041A (pt) | 2004-10-26 |
TW200302735A (en) | 2003-08-16 |
WO2003061620A3 (en) | 2003-10-16 |
PE20030973A1 (es) | 2003-12-09 |
EP1467740A1 (en) | 2004-10-20 |
AR047005A1 (es) | 2006-01-04 |
US20080160074A1 (en) | 2008-07-03 |
TWI283181B (en) | 2007-07-01 |
US20040013718A1 (en) | 2004-01-22 |
JP2005515243A (ja) | 2005-05-26 |
US20030175334A1 (en) | 2003-09-18 |
TW200302281A (en) | 2003-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200400888A1 (ru) | Фармацевтически приемлемые тельца, несущие фосфат глицерина | |
ATE465164T1 (de) | Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
EA200600076A1 (ru) | Композиции и способы увеличения активности теломеразы | |
PL371428A1 (en) | Substituted indolizine-like compounds and methods of use | |
MEP42808A (en) | Use of flibanserin in the treatment of sexual disorders | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
EA201290878A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ | |
EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
DE602005010876D1 (de) | Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen | |
ATE453646T1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
TW200612969A (en) | 3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof | |
DE60320095D1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
MX344732B (es) | Formulacion estable de mia/cd-rap. | |
HUP0400548A2 (hu) | Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására | |
EA201071275A1 (ru) | Конденсированные соединения пиразина, которые можно использовать для лечения дегенеративных и воспалительных заболеваний | |
EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
MA31630B1 (fr) | Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique | |
ATE311191T1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
MXPA05010416A (es) | Combinacion de substancias activas de aceites minerales que contienen acidos grasos (3 con extractos vegetales que contengan polifenoles y su uso. | |
WO2004100893A3 (en) | Methods for treatment of inflammatory diseases using ct-3 or analogs thereof | |
EA201291442A1 (ru) | Комбинированная терапия с криохирургией и имиквимодом с низкой дозировкой для лечения актинического кератоза | |
IS6555A (is) | Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni | |
MX2022010945A (es) | Usos terapeuticos de compuestos macrociclicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |